FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma

FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma

Abstract Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months....

Full description

Bibliographic Details
Main Authors:	Luke S. McLean, Karda Cavanagh, Rodney J. Hicks, Jason Callahan, Jing Xie, Anthony Cardin, Annette M. Lim, Danny Rischin
Format:	Article
Language:	English
Published:	BMC 2021-10-01
Series:	Cancer Imaging
Subjects:	Cutaneous cancer Immunotherapy FDG-PET PERCIST1.0 RECIST1.1
Online Access:	https://doi.org/10.1186/s40644-021-00426-2

Similar Items

FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review
by: Fredrik Helland, et al.
Published: (2019-08-01)

Role of 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in assessment of neoadjuvant chemotherapy response in breast cancer patients
by: Eslam Abdul Salam Sarhan, et al.
Published: (2020-07-01)

Radioembolization-Induced Changes in Hepatic [<sup>18</sup>F]FDG Metabolism in Non-Tumorous Liver Parenchyma
by: Manon N. Braat, et al.
Published: (2022-10-01)

Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
by: Annette M. Lim, et al.
Published: (2021-04-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)

Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma
by: Marwa Mohammed Hasan Tawfik, et al.
Published: (2020-05-01)

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 2
by: Akshay D. Baheti, et al.
Published: (2019-08-01)

Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
by: Karda Cavanagh, et al.
Published: (2024-03-01)

Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
by: Luke S. McLean, et al.
Published: (2022-01-01)

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
by: Vivek Subbiah, et al.
Published: (2017-02-01)

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
by: Angelo Castello, et al.
Published: (2020-07-01)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
by: Malene Grubbe Hildebrandt, et al.
Published: (2019-08-01)

EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
by: Charline Lasnon, et al.
Published: (2017-05-01)

QUANTITATIVE EVALUATION OF THERAPEUTIC RESPONSE BY FDG PET-CT IN METASTATIC BREAST CANCER
by: Dorothée eGOULON, et al.
Published: (2016-05-01)

Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma
by: Tyler J Wellman, et al.
Published: (2023-11-01)

Influence of metabolic tumor burden on reference tissues’ standardized uptake values in 18F-FDG PET/CT sequential imaging
by: Ahmed Badawy, et al.
Published: (2023-11-01)

Diffusion-weighted MR imaging diagnostic merits in the post-therapeutic assessment of musculoskeletal soft tissue sarcoma
by: Amr Farouk Ibrahim Moustafa, et al.
Published: (2019-11-01)

Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow
by: Jeffrey P. Leal, et al.
Published: (2022-11-01)

A method for evaluation of patient-specific lean body mass from limited-coverage CT images and its application in PERCIST: comparison with predictive equation
by: Jingjie Shang, et al.
Published: (2021-02-01)

Is CT or FDG-PET more useful for evaluation of the treatment response in metastatic HER2-positive breast cancer? a case report and literature review
by: Hirotaka Suto, et al.
Published: (2023-04-01)

Immunotherapy Assessment: A New Paradigm for Radiologists
by: Vincenza Granata, et al.
Published: (2023-01-01)

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST
by: Marianne Vogsen, et al.
Published: (2021-04-01)

Automatic segmentation of hepatic metastases on DWI images based on a deep learning method: assessment of tumor treatment response according to the RECIST 1.1 criteria
by: Xiang Liu, et al.
Published: (2022-12-01)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
by: Ying Xu, et al.
Published: (2022-05-01)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
by: Lucas Goldfarb, et al.
Published: (2019-01-01)

A European Society of Oncologic Imaging (ESOI) survey on the radiological assessment of response to oncologic treatments in clinical practice
by: Giovanni Cappello, et al.
Published: (2023-12-01)

Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
by: Jonas S. Sørensen, et al.
Published: (2020-11-01)

Evaluation of liver tumour response by imagingKey points
by: Jules Gregory, et al.
Published: (2020-06-01)

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
by: Roberta Ambrosini, et al.
Published: (2020-05-01)

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
by: Hubert Beaumont, et al.
Published: (2021-09-01)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Hyo Jung Park, et al.
Published: (2021-01-01)

Usefulness of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma
by: Takahiro Yokose, et al.
Published: (2020-06-01)

Scar sarcoidosis on 18F-FDG PET/CT
by: Saurabh Arora, et al.
Published: (2019-06-01)

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST
by: Mauricio Canals L, et al.

Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments
by: Inka Ristow, et al.
Published: (2024-02-01)

Are radiologists ready to evaluate true response to immunotherapy?
by: Inci Kizildag Yirgin, et al.
Published: (2021-02-01)

Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
by: Alesha A. Thai, et al.
Published: (2021-11-01)

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT
by: David A. Pattison, et al.
Published: (2019-02-01)

A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
by: Junjie Hu, et al.
Published: (2022-12-01)

Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images
by: Jia Tan, et al.
Published: (2022-12-01)